Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

Nature

Volumn 523, Issue 7560, 2015, Pages 347-351

  Li, Zhenfei ^a   Bishop, Andrew C ^a   Alyamani, Mohammad ^a   Garcia, Jorge A ^a,b   Dreicer, Robert ^a,b   Bunch, Dustin ^a   Liu, Jiayan ^c   Upadhyay, Sunil K ^c   Auchus, Richard J ^c   Sharifi, Nima ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; CYTOCHROME P450 17; DRUG METABOLITE; ENZALUTAMIDE; STEROID 5ALPHA REDUCTASE 2; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANE DERIVATIVE; CHROMATIN; DELTA4-ABIRATERONE; PHENYLTHIOHYDANTOIN; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANDROGEN; ANTAGONISM; DISEASE TREATMENT; ENZYME; METABOLISM; RODENT; STEROID; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STEROIDOGENESIS; XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BIOTRANSFORMATION; CELL DIVISION; CHEMISTRY; CHROMATIN; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS;

MUS;

3-HYDROXYSTEROID DEHYDROGENASES; 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANDROSTENES; ANIMALS; BIOSYNTHETIC PATHWAYS; BIOTRANSFORMATION; CELL DIVISION; CHROMATIN; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937572793     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14406     Document Type: Article

References (26)

1. Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin.Cancer Res. 11, 4653-4657 (2005).
2. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454 (2008).
3. Chang, K. H. et al. A gain-of-function mutation in DHT synthesis in castrationresistant prostate cancer. Cell 154, 1074-1084 (2013).
4. Knudsen, K. E. & Penning, T. M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab. 21, 315-324 (2010).
5. Chang, K. H. & Sharifi, N. Prostate cancer-from steroid transformations to clinical translation. Nature Rev. Urol. 9, 721-724 (2012).
6. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
7. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
8. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
9. Beer, T.M. et al. Enzalutamide inmetastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424-433 (2014).
10. Li, R. et al. Abiraterone inhibits 3b-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin. Cancer Res. 18, 3571-3579 (2012).
11. Ferraldeschi, R.,Sharifi,N.,Auchus,R. J.&Attard,G.Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin. Cancer Res. 19, 3353-3359 (2013).
12. Garrido, M. et al. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone. J. Steroid Biochem. Mol. Biol. 143, 1-10 (2014).
13. Chang, K. H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728-13733 (2011).
14. Richards, J. et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 72, 2176-2182 (2012).
15. Hodgson,M.C. et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 280, 6511-6519 (2005).
16. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
17. Carreira, S. et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
18. Balk, S. Emerging developments in abiraterone resistance. In Proc. American Association for Cancer Research ProstateCancer FoundationConference onAdvances in Prostate Cancer Research. Abstr. IA11 (American Association for Cancer Research, 2014).
19. Attard, G. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507-516 (2012).
20. Efstathiou, E. et al. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 32, abstr. 5000 (2014).
21. Fizazi, K. et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients withmetastatic castration-resistant prostate cancer that has progressed during or following docetaxel-based therapy: ELM-PC 5. J. Clin. Oncol. 33, 723-731 (2015).
22. Papari-Zareei, M., Brandmaier, A. & Auchus, R. J. Arginine 276 controls the directional preference of AKR1C9 (rat liver 3a-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells. Endocrinology 147, 1591-1597 (2006).
23. Li, Z., Nie, F., Wang, S. & Li, L. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc. Natl Acad. Sci. USA 108, 3116-3123 (2011).
24. Evaul, K., Li, R., Papari-Zareei, M., Auchus, R. J. & Sharifi, N. 3b-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151, 3514-3520 (2010).
25. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
26. Kushnir,M.M. et al. Liquid chromatography-tandemmass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 56, 1138-1147 (2010).